Literature DB >> 3346542

Effect of gangliosides on activation of the alternative pathway of human complement.

M T Michalek1, E G Bremer, C Mold.   

Abstract

Liposomes as defined model membranes were used to quantitatively study the effects of specific sialic acid containing glycolipids on activation of the alternative pathway of human C. Liposomes containing dimyristoylphosphatidylethanolamine, cholesterol, and cerebrosides at molar ratios of 1.0/0.75/0.33 activated the alternative pathway in human serum treated with MgEGTA. Activation was measured by C3 conversion and the deposition of total C3 and functional C3b on the liposome surface. The monosialoganglioside GM1, when incorporated into the activating liposome membrane at molar ratios between 10(-5) and 10(-2), inhibited activation in a dose-dependent manner. Sialosylparagloboside also inhibited activation in human serum, and inhibition was completely reversed after neuraminidase treatment. The degree of inhibition by GM1 correlated with the relative amount of GM1 exposed on the liposome surface. Sialic acid did not directly inhibit the binding of C3b when liposomes containing gangliosides were incubated with the purified components C3, B, D, and P. GM1 did inhibit activation when liposomes were incubated with a mixture of purified C3, B, D, P, H, and I. Binding assays with radiolabeled H showed increased binding of H to liposome-bound C3b in the presence of GM1. These results establish the ability of sialic acid on glycolipids to promote H binding to C3b and thereby regulate alternative pathway activation on a defined lipid membrane.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346542

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.

Authors:  G Triolo; E Giardina; D Casiglia; G Scarantino; G D Bompiani
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

2.  Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

Authors:  Michael P Malakhov; Laura M Aschenbrenner; Donald F Smee; Miles K Wandersee; Robert W Sidwell; Larisa V Gubareva; Vasiliy P Mishin; Frederick G Hayden; Do Hyong Kim; Alice Ing; Erin R Campbell; Mang Yu; Fang Fang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 3.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  H Nakakuma; T Kawaguchi; K Horikawa; M Hidaka; Y Yonemura; M Kawakita; T Kagimoto; M Iwamori; Y Nagai; K Takatsuki
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

5.  Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis.

Authors:  M Susani; M Schulze; M Exner; D Kerjaschki
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

6.  Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.

Authors:  Satu Hyvärinen; Koji Uchida; Markku Varjosalo; Reija Jokela; T Sakari Jokiranta
Journal:  J Biol Chem       Date:  2013-12-16       Impact factor: 5.157

7.  A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae.

Authors:  S Ram; A K Sharma; S D Simpson; S Gulati; D P McQuillen; M K Pangburn; P A Rice
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

8.  Requirement for sialic acid on the endothelial ligand of a lymphocyte homing receptor.

Authors:  D D True; M S Singer; L A Lasky; S D Rosen
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

9.  Podoplanin: emerging functions in development, the immune system, and cancer.

Authors:  Jillian L Astarita; Sophie E Acton; Shannon J Turley
Journal:  Front Immunol       Date:  2012-09-12       Impact factor: 7.561

10.  Stealth properties to improve therapeutic efficacy of drug nanocarriers.

Authors:  Stefano Salmaso; Paolo Caliceti
Journal:  J Drug Deliv       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.